BioPharma Resources

Drug Trial Radar · NCT07495033

Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

May 31, 2029

Study completion May 31, 2030

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Interstitial lung disease (ILD) is a common pulmonary manifestation in chronic tissue diseases (CTD), significantly affecting patient's prognosis. The main purpose of this study is to evaluate the efficacy of telitacicept compared with placebo in slowing down the decline in lung volume in patients with interstitial lung disease associated with connective tissue disease (CTD-ILD) on the basis of standard treatment.

Conditions

  • CTD-ILD

Interventions

  • TelitaciceptDrug

    Subjects will receive Telitacicept.

  • PlaceboDrug

    The placebo contains no active ingredients. To maintain the blind, the placebo matches the active drug in all physical aspects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in FVC(mL) at Week 52Time frame: Baseline and Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.